For its second fiscal quarter (ending June 30), ANI Pharmaceuticals Inc (NASDAQ: ANIP) has reported a -147% decline in E.P.S. from $0.30 a year ago to $-0.14 in the current quarter. This performance was $-1.08 short of the consensus estimate of $0.94. E.P.S. were $1.21 for the latest four quarters through June 30 versus $-0.47 for the same period a year ago.
Recent Price Action
ANI Pharmaceuticals Inc (NASDAQ: ANIP) stock closed at $63.29 on 8/6/24 after a very large increase of 7.0%. Moreover, unusually high trading volume at 163% of normal accompanied the advance. The stock is unchanged during the last week but has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
ANIP is expected to continue to be an important Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
ANI Pharmaceuticals has a current Value Trend Rating of B (Positive). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. ANI Pharmaceuticals has a neutral Appreciation Score of 52 but a good Power Rating of 76, triggering the Positive Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment